

Supplementary Material

Supplementary Methods

RSV and influenza testing in Japan

In Japan, RSV and influenza tests are covered by national health insurance (NHI) and most healthcare facilities use rapid antigen kit for testing. For RSV testing any of the following groups are covered under NHI: (1) outpatient infants less than 1 year of age, (2) any hospitalized child, or (3) children eligible for palivizumab (note that the test is covered by NHI if any one of these criteria applies). For influenza testing, any outpatient is covered by insurance, regardless of age.

Influenza vaccination coverage and influenza antiviral use in Japan

Influenza vaccination coverage among children in Japan is approximately 50-60%, which is similar to the United States (U.S.).^{1,2} Outpatient antiviral use for influenza is reported to be more common among young children diagnosed for influenza in Japan (approximately 80%) compared to in the U.S. (approximately 40%).^{3,4}

Database

This retrospective cohort study was conducted using data from the Medical Data Vision (MDV) database, one of the largest electronic health records databases in Japan covering approximately 450 hospitals (25% of acute care hospitals in Japan) which includes data for over 40 million people. The MDV database includes detailed data on inpatient and outpatient encounters, drugs prescribed, diagnoses, laboratory tests performed, and medical practice (e.g., date of visit, department visited) from these hospitals.

Definition of seasonality

Seasons were defined for each year based on the epidemic curves for RSV observed annually between 2011 and 2022 by the NESID. Seasons for 2011 to 2019 were defined as beginning on May 1 of each year and ending on April 30 of the following year. Due to COVID-19 pandemic, May to December for 2020 was defined as a non-epidemic period. Since RSV seasonality was irregular after 2021, 2021 and 2022 seasons were defined as January to December (note: the study period ended on July 31, 2022, so the 2022 season was only half as long as a full season).

Definition of healthy infants

Since the MDV database may over-represent individuals with comorbidities/prematurity given it is data from acute care hospitals, some analyses were also performed by restricting to a population of “healthy children” who had no claim of the select comorbidities or prematurity (described above) and no palivizumab use.

Data on COVID-19

We initially included analysis of COVID-19 as part of the study protocol. However, data on COVID-19 were excluded from the analyses as there were very few related hospitalizations (n=14) which may be because hospitalization with COVID-19 was relatively rare during the study period and these patients were concentrated in certain hospitals that had capacity to admit COVID-19 patients (e.g., pediatric COVID-19 ward). It is likely many of these hospitals were not included in the database.

References

1. Ministry of Health Labour and Welfare. About the Seasonal Influenza Vaccine for the 2023/2024 Season. <https://www.mhlw.go.jp/content/10906000/001146456.pdf>. Accessed December 23, 2023. (In Japanese)
2. Centers for Disease Control and Prevention. Flu Vaccination Coverage, United States, 2022–23 Influenza Season. <https://www.cdc.gov/flu/fluview/coverage-2223estimates.htm>. Accessed December 23, 2023.
3. Okubo Y, Uda K, Miyairi I. Trends in Influenza and Related Health Resource Use During 2005–2021 Among Children in Japan. *J Pediatr Infect Dis* 2023;42:648-53.
4. Antoon JW, Sarker J, Abdelaziz A, et al. Trends in outpatient influenza antiviral use among children and adolescents in the United States. *Pediatrics*. 2023;152(6):e2023061960.

Supplementary Table 1. Relevant ICD-10 codes for conditions of interest

Condition	ICD-10 codes	Detailed description
Index disease		
RSV	J12.1	Respiratory syncytial virus pneumonia
RSV	J20.5	RSV bronchitis
RSV	J21.0	RSV bronchiolitis
RSV	B34.8	RSV infection
RSV	B97.4	RSV bronchitis
Influenza	J09	Novel influenza (H1N1)
Influenza	J10.1	Influenza A/USSR
Influenza	J11.0	Influenza pneumonia
Influenza	J11.1	Influenza
Comorbidities of interest		
Down syndrome	Q90.9	
Asthma	J45.9	
Bronchitis	J40	
Congenital heart disease	I27.8, I51.0, Q20.0-5, Q20.8-Q21.4, Q21.8-Q22.6, Q22.8, Q23.0-4, Q23.8-Q24.4, Q24.5, Q24.8-9, Q25.1, Q25.3-Q264, Q26.8, Q26.9	
Bronchopulmonary dysplasia	P27.1	
Prematurity	P07.3	
Immunodeficiency	D70.0, D71.0, D72.0, D84.9, D80.0-2, D80.4, D80.5, D80.9, D81.0, D81.9, D82.0, D82.1, D82.3, D83.0, D83.9, D84.0, D84.8, D89.1, D89.8, M35.9, Z21.0, Z94.0, Z94.1, Z94.2, Z94.3, Z94.4, Z94.8	
Intellectual developmental delay	F70-F79	
Children under supportive medical care	Japanese medical segment (kubun) codes: C101-2 – C116	
Pulmonary hypoplasia	Q33.6	
Airway stenosis	J98.8	
Esophageal atresia	Q39.3	
Congenital metabolic disorders	D52.8, E55.21, E70.0, E70.1, E70.2, E70.9, E71.0, E71.1, E71.3 E72.0, E72.1, E72.2, E72.3, E72.4, E72.9, E73.0, E74.0, E74.2, E74.4, E74.8, E74.9, E75.2, E75.5, E77.0, E77.8, E77.9, E78.0, E78.9, E79.0, E79.8, E83.0, E88.0, E88.8, E88.9, G60.1, G71.3, G90.8. P09.1	
Cystic fibrosis	E84.9	
Neuromuscular disorders	G10-14, G60, G70-73, G80-83, G90-99	
Complications		
Pneumonia	A40.3, A41.9, A49.1, G00.1, I30.1, J11.0, J12.1, J12.9, J13, J14, J15.1, J15.2, J15.4, J15.6, J15.9, J18.0, J18.1, J18.8, J18.9, J20.2, J69.0, J84.1, J84.9, J85.0, J85.1, J95.8, K65.0, U07.1	
Otitis media	H65.0, H66.4, H66.0, H66.9, H65.1, H65.9, H67.0, H67.1	
Febrile seizure	R56.0	
Encephalitis or encephalopathy	G00-G09, G41	

Myocarditis	J11.8, I40.0, I40.9, I51.4
-------------	----------------------------

**ICD-10 coding limited to codes used by the Japanese healthcare system to identify the conditions of interest and are covered in the dataset*

Supplementary Table 2. Baseline characteristics of all children <5 years of age who were diagnosed in the outpatient setting with RSV infection and influenza

	RSV					Influenza				
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n relative % by age group)	176,911 (100)	70,021 (39.6)	39,311 (22.2)	42,485 (24.0)	25,094 (14.2)	153,383 (100)	8,741 (5.7)	16,295 (10.6)	39,218 (25.6)	89,129 (58.1)
Sex, n (%)										
Female	79,746 (45.1)	30,989 (44.3)	17,235 (43.8)	19,506 (45.9)	12,016 (47.9)	70,589 (46.0)	3,881 (44.4)	7,476 (45.9)	18,156 (46.3)	41,076 (46.1)
Male	97,165 (54.9)	39,032 (55.7)	22,076 (56.2)	22,979 (54.1)	13,078 (52.1)	82,794 (54.0)	4,860 (55.6)	8,819 (54.1)	21,062 (53.7)	48,053 (53.9)
Age, months										
Mean (SD)	11.8 (11.6)	2.5 (1.5)	8.3 (1.7)	16.6 (3.4)	35.0 (9.2)	29.8 (16.8)	3.1 (1.4)	8.8 (1.7)	17.1 (3.4)	41.9 (10.5)
Median (IQR)	8.0 (3.0-17.0)	2.0 (1.0-4.0)	8.0 (7.0-10.0)	16.0 (14.0-19.0)	33.0 (27.0-41.0)	28.0 (15.0-45.0)	3.0 (2.0-4.0)	9.0 (7.0-10.0)	17.0 (14.0-20.0)	42.0 (33.0-51.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	4,191 (2.4)	1,344 (1.9)	877 (2.2)	1,199 (2.8)	771 (3.1)	8,308 (5.5)	198 (2.3)	600 (3.7)	1,816 (4.7)	5,694 (6.4)
2012 (May 2012 to April 2013)	8,239 (4.7)	2,985 (4.3)	2,052 (5.2)	2,022 (4.8)	1,180 (4.7)	8,619 (5.7)	312 (3.6)	721 (4.5)	1,998 (5.1)	5,588 (6.3)
2013 (May 2013 to April 2014)	11,285 (6.4)	4,545 (6.5)	2,756 (7.0)	2,559 (6.0)	1,425 (5.7)	13,432 (8.8)	523 (6.0)	1,224 (7.6)	3,334 (8.5)	8,351 (9.4)
2014 (May 2014 to April 2015)	16,909 (9.6)	6,678 (9.5)	3,946 (10.0)	3,958 (9.3)	2,327 (9.3)	18,084 (11.9)	915 (10.5)	1,754 (10.8)	4,590 (11.8)	10,825 (12.2)
2015 (May 2015 to April 2016)	18,853 (10.7)	7,362 (10.5)	4,596 (11.7)	4,433 (10.4)	2,462 (9.8)	19,960 (13.1)	858 (9.8)	2,061 (12.7)	5,055 (13.0)	11,986 (13.6)
2016 (May 2016 to April 2017)	18,242 (10.3)	7,330 (10.5)	4,351 (11.1)	4,318 (10.2)	2,243 (9.0)	18,560 (12.2)	1,096 (12.6)	2,038 (12.6)	4,978 (12.8)	10,448 (11.8)

2017 (May 2017 to April 2018)	25,404 (14.4)	9,486 (13.6)	6,048 (15.4)	6,346 (15.0)	3,524 (14.1)	24,544 (16.1)	1,496 (17.2)	2,785 (17.2)	6,232 (16.0)	14,031 (15.9)
2018 (May 2018 to April 2019)	23,143 (13.1)	9,561 (13.7)	5,315 (13.5)	5,499 (13.0)	2,768 (11.0)	22,129 (14.5)	1,683 (19.3)	2,575 (15.9)	5,706 (14.6)	12,165 (13.8)
2019 (May 2019 to April 2020)	20,601 (11.7)	8,311 (11.9)	4,481 (11.4)	5,172 (12.2)	2,637 (10.5)	16,333 (10.7)	1,255 (14.4)	2,093 (12.9)	4,473 (11.5)	8,512 (9.6)
2020 (May to December)	3,896 (2.2)	2,583 (3.7)	679 (1.7)	475 (1.1)	159 (0.6)	411 (0.3)	70 (0.8)	78 (0.5)	173 (0.4)	90 (0.1)
2021 (January to December)	21,121 (12.0)	7,858 (11.2)	3,350 (8.5)	5,363 (12.6)	4,550 (18.2)	1,101 (0.7.0)	171 (2.0)	160 (1.0)	441 (1.1)	329 (0.4)
2022 (January to July)	4,913 (2.8)	1,946 (2.8)	838 (2.1)	1,105 (2.6)	1,024 (4.1)	948 (0.6)	146 (1.7)	128 (0.8)	223 (0.6)	451 (0.5)
Comorbidity during baseline period, n (%)										
Down syndrome	1,785 (1.0)	975 (1.4)	367 (0.9)	262 (0.6)	181 (0.7)	189 (0.1)	24 (0.3)	55 (0.3)	48 (0.1)	62 (0.1)
Congenital heart disease	9,150 (5.2)	5,717 (8.2)	2,065 (5.3)	968 (2.3)	400 (1.6)	1,123 (0.7)	231 (2.6)	396 (2.4)	277 (0.7)	219 (0.3)
Bronchopulmonary dysplasia	579 (0.3)	228 (0.3)	213 (0.5)	96 (0.2)	42 (0.2)	57 (0.0)	12 (0.1)	17 (0.1)	14 (0.0)	14 (0.0)
Prematurity	21,686 (12.3)	17,297 (24.7)	3,288 (8.4)	760 (1.8)	341 (1.4)	851 (0.6)	253 (2.9)	456 (2.8)	118 (0.3)	24 (0.0)
Immunodeficiency	795 (0.5)	370 (0.5)	201 (0.5)	134 (0.3)	90 (0.4)	329 (0.2)	39 (0.5)	62 (0.4)	75 (0.2)	153 (0.2)
Pulmonary hypoplasia	78 (0.0)	43 (0.1)	22 (0.1)	9 (0.0)	4 (0.0)	13 (0.0)	3 (0.0)	7 (0.0)	1 (0.0)	2 (0.0)
Airway stenosis	121 (0.1)	30 (0.0)	46 (0.1)	32 (0.1)	13 (0.1)	31 (0.0)	8 (0.1)	8 (0.1)	5 (0.0)	10 (0.0)
Esophageal atresia	6 (0.0)	3 (0.0)	0 (0.0)	3 (0.0)	0 (0.0)	2 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	1 (0.0)

Congenital metabolic disorder	1,382 (0.8)	492 (0.7)	374 (1)	311 (0.7)	205 (0.8)	780 (0.5)	48 (0.6)	108 (0.7)	249 (0.6)	375 (0.4)
Neuromuscular disorder	1,078 (0.6)	356 (0.5)	243 (0.6)	267 (0.6)	212 (0.8)	638 (0.4)	27 (0.3)	89 (0.6)	220 (0.6)	302 (0.3)
Cystic fibrosis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
No record of these comorbidities	144,611 (81.7)	47,061 (67.2)	33,654 (85.6)	40,077 (94.3)	23,819 (94.9)	149,947 (97.8)	8,203 (93.8)	15,318 (94.0)	38,329 (97.7)	88,097 (98.8)
Palivizumab use, n (%)										
Yes	16,940 (9.6)	12,356 (17.7)	3,265 (8.3)	1,172 (2.8)	147 (0.6)	1,131 (0.7)	146 (1.7)	404 (2.5)	487 (1.2)	94 (0.1)
No record of use	159,971 (90.4)	57,665 (82.4)	36,046 (91.7)	41,313 (97.2)	24,947 (99.4)	152,252 (99.3)	8,595 (98.3)	15,891 (97.5)	38,731 (98.8)	89,035 (99.9)
Size of healthcare facilities, n (%)										
Less than 200 beds	13,135 (7.4)	4,296 (6.1)	3,327 (8.5)	3,462 (8.2)	2,050 (8.2)	14,403 (9.4)	412 (4.7)	1,310 (8.0)	3,599 (9.2)	9,082 (10.2)
200 to 499 beds	97,448 (55.1)	35,523 (50.7)	23,038 (58.6)	24,579 (57.9)	14,308 (57.0)	95,370 (62.2)	4,694 (53.7)	9,971 (61.2)	24,243 (61.8)	56,462 (63.4)
500 or more beds	66,328 (37.5)	30,202 (43.1)	12,946 (32.9)	14,444 (34.0)	8,736 (34.8)	43,610 (28.4)	3,635 (41.6)	5,014 (30.8)	11,376 (29.0)	23,585 (26.5)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 3 Baseline characteristics of healthy children <5 years of age who were diagnosed in the outpatient setting with RSV infection and influenza

	RSV					Influenza				
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n (relative % by age group)	141,843 (100)	45,318 (31.9)	33,225 (23.4)	39,545 (27.9)	23,755 (16.7)	149,529 (100)	8,197 (5.5)	15,277 (10.2)	38,019 (25.4)	88,036 (58.9)
Sex, n (%)										
Female	63,794 (45.0)	19,792 (43.7)	14,462 (43.5)	18,158 (45.9)	11,382 (47.9)	68,883 (46.1)	3,643 (44.4)	7,016 (45.9)	17,600 (46.3)	40,624 (46.1)
Male	78,049 (55.0)	25,526 (56.3)	18,763 (56.5)	21,387 (54.1)	12,373 (52.1)	80,646 (53.9)	4,554 (55.6)	8,261 (54.1)	20,419 (53.7)	47,412 (53.9)
Age, months										
Mean (SD)	13.3 (11.9)	2.7 (1.4)	8.4 (1.7)	16.6 (3.4)	35.0 (9.2)	30.1 (16.7)	3.1 (1.4)	8.8 (1.7)	17.1 (3.4)	41.9 (10.5)
Median (IQR)	10.0 (4.0-19.0)	3.0 (2.0-4.0)	8.0 (7.0-10.0)	16.0 (14.0-19.0)	33.0 (27.0-41.0)	29.0 (15.0-45.0)	3.0 (2.0-4.0)	9.0 (7.0-10.0)	17.0 (14.0-20.0)	42.0 (33.0-51.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	3,671 (2.6)	1,063 (2.3)	801 (2.4)	1,101 (2.8)	706 (3.0)	8,198 (5.5)	191 (2.3)	571 (3.8)	1,785 (4.7)	5,651 (6.5)
2012 (May 2012 to April 2013)	6,880 (4.9)	2,224 (4.9)	1,722 (5.2)	1,839 (4.7)	1,095 (4.6)	8,474 (5.7)	300 (3.7)	689 (4.5)	1,957 (5.2)	5,528 (6.3)
2013 (May 2013 to April 2014)	8,962 (6.3)	3,161 (7.0)	2,199 (6.6)	2,290 (5.8)	1,312 (5.5)	13,133 (8.8)	496 (6.1)	1,133 (7.5)	3,255 (8.6)	8,249 (9.4)
2014 (May 2014 to April 2015)	13,808 (9.7)	4,610 (10.2)	3,385 (10.2)	3,662 (9.3)	2,151 (9.1)	17,659 (11.9)	860 (10.5)	1,652 (10.9)	4,452 (11.8)	10,695 (12.2)
2015 (May 2015 to April 2016)	15,391 (10.9)	5,114 (11.3)	3,881 (11.7)	4,128 (10.4)	2,268 (9.6)	19,475 (13.1)	803 (9.8)	1,923 (12.7)	4,908 (13.0)	11,841 (13.6)
2016 (May 2016 to April 2017)	14,698 (10.4)	4,917 (10.9)	3,672 (11.1)	4,016 (10.2)	2,093 (8.8)	18,068 (12.2)	1,032 (12.6)	1,892 (12.4)	4,819 (12.7)	10,325 (11.8)

2017 (May 2017 to April 2018)	21,058 (14.9)	6,623 (14.6)	5,240 (15.8)	5,862 (14.8)	3,333 (14.0)	23,843 (16.0)	1,389 (17.0)	2,613 (17.2)	5,999 (15.9)	13,842 (15.8)
2018 (May 2018 to April 2019)	18,823 (13.3)	6,395 (14.1)	4,602 (13.9)	5,174 (13.1)	2,652 (11.2)	21,540 (14.5)	1,566 (19.1)	2,431 (16.0)	5,529 (14.6)	12,014 (13.7)
2019 (May 2019 to April 2020)	16,484 (11.6)	5,130 (11.3)	3,916 (11.8)	4,888 (12.4)	2,550 (10.7)	15,880 (10.7)	1,182 (14.4)	1,966 (12.9)	4,322 (11.4)	8,410 (9.6)
2020 (May to December)	1,162 (0.8)	363 (0.8)	280 (0.8)	376 (1.0)	143 (0.6)	376 (0.3)	59 (0.7)	66 (0.4)	168 (0.4)	83 (0.1)
2021 (January to December)	17,211 (12.1)	4,782 (10.6)	2,868 (8.6)	5,132 (13.0)	4,429 (18.7)	1,026 (0.7)	162 (2.0)	143 (0.9)	413 (1.1)	308 (0.4)
2022 (January to July)	3,587 (2.5)	906 (2.0)	638 (1.9)	1,043 (2.6)	1,000 (4.2)	912 (0.6)	140 (1.7)	122 (0.8)	214 (0.6)	436 (0.5)
Size of healthcare facilities, n (%)										
Less than 200 beds	11,318 (8.0)	3,069 (6.8)	2,951 (8.9)	3,312 (8.4)	1,986 (8.4)	14,273 (9.5)	401 (4.9)	1,281 (8.4)	3,555 (9.4)	9,036 (10.3)
200 to 499 beds	83,300 (58.7)	25,757 (56.8)	20,393 (61.4)	23,359 (59.1)	13,791 (58.1)	93,555 (62.6)	4,447 (54.3)	9,467 (62.0)	23,700 (62.3)	55,941 (63.5)
500 or more beds	47,225 (33.3)	16,492 (36.4)	9,881 (29.7)	12,874 (32.6)	7,978 (33.6)	41,701 (27.9)	3,349 (40.9)	4,529 (29.6)	10,764 (28.3)	23,059 (26.2)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 4. Baseline characteristics for healthy children hospitalized with RSV infection and influenza overall and by age categories

	RSV					Influenza				
	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years	Total	Age <6 months	Age 6-11 months	Age 1<2 years	Age 2<5 years
Total number of patients, n (relative % by age group)	85,550 (100)	32,909 (38.5)	17,618 (20.6)	23,046 (26.9)	11,977 (14.0)	10,764 (100)	2,064 (19.2)	1,100 (10.2)	2,728 (25.3)	4,872 (45.3)
Sex, n (%)										
Female	38,766 (45.3)	14,508 (44.1)	7,489 (42.5)	10,741 (46.6)	6,028 (50.3)	4,696 (43.6)	952 (46.1)	478 (43.5)	1,228 (45.0)	2,038 (41.8)
Male	46,784 (54.7)	18,401 (55.9)	10,129 (57.5)	12,305 (53.4)	5,949 (49.7)	6,068 (56.4)	1,112 (53.9)	622 (56.5)	1,500 (55.0)	2,834 (58.2)
Age, months										
Mean (SD)	11.9 (11.2)	2.5 (1.4)	8.4 (1.7)	16.7 (3.4)	33.9 (8.6)	24.2 (17.4)	2.5 (1.3)	8.6 (1.7)	17.4 (3.4)	40.7 (10.6)
Median (IQR)	9.0 (3.0-17.0)	2.0 (1.0-4.0)	8.0 (7.0-10.0)	16.0 (14.0-19.0)	31.0 (27.0-39.0)	21.0 (9.0-38.5)	2.0 (2.0-3.0)	9.0 (7.0-10.0)	17.0 (14.0-20.0)	40.0 (31.0-50.0)
Season by year, n (%)										
2011 (May 2011 to April 2012)	1,911 (2.2)	684 (2.1)	428 (2.4)	530 (2.3)	269 (2.2)	353 (3.3)	68 (3.3)	36 (3.3)	78 (2.9)	171 (3.5)
2012 (May 2012 to April 2013)	3,448 (4.0)	1,297 (3.9)	799 (4.5)	911 (4.0)	441 (3.7)	496 (4.6)	97 (4.7)	41 (3.7)	124 (4.6)	234 (4.8)
2013 (May 2013 to April 2014)	4,925 (5.8)	2,105 (6.4)	1,093 (6.2)	1,169 (5.1)	558 (4.7)	900 (8.4)	141 (6.8)	91 (8.3)	216 (7.9)	452 (9.3)
2014 (May 2014 to April 2015)	7,587 (8.9)	2,987 (9.1)	1,684 (9.6)	1,961 (8.5)	955 (8.0)	1,088 (10.1)	251 (12.2)	107 (9.8)	254 (9.3)	476 (9.8)
2015 (May 2015 to April 2016)	8,975 (10.5)	3,565 (10.8)	1,923 (10.9)	2,366 (10.3)	1,121 (9.4)	1,507 (14.0)	225 (10.9)	188 (17.1)	384 (14.1)	710 (14.6)
2016 (May 2016 to April 2017)	8,375 (9.8)	3,343 (10.2)	1,906 (10.8)	2,214 (9.6)	912 (7.6)	1,334 (12.4)	293 (14.2)	119 (10.8)	337 (12.4)	585 (12.1)

2017 (May 2017 to April 2018)	12,640 (14.8)	4,763 (14.5)	2,798 (15.9)	3,436 (14.9)	1,643 (13.7)	1,612 (15.0)	292 (14.2)	162 (14.8)	381 (14.0)	777 (16.0)
2018 (May 2018 to April 2019)	11,639 (13.6)	4,739 (14.4)	2,556 (14.5)	3,034 (13.2)	1,310 (10.9)	1,818 (16.9)	401 (19.5)	173 (15.8)	469 (17.2)	775 (16.0)
2019 (May 2019 to April 2020)	11,031 (12.9)	4,107 (12.5)	2,252 (12.8)	3,217 (14.0)	1,455 (12.2)	1,608 (15.0)	288 (14.0)	177 (16.1)	474 (17.4)	669 (13.8)
2020 (May to December)	711 (0.8)	239 (0.7)	151 (0.9)	231 (1.0)	90 (0.8)	3 (0.0)	1 (0.0)	2 (0.2)	0 (0.0)	0 (0.0)
2021 (January to December)	11,924 (13.9)	4,261 (13.0)	1,671 (9.5)	3,341 (14.5)	2,651 (22.1)	6 (0.1)	1 (0.0)	1 (0.1)	3 (0.1)	1 (0.0)
2022 (January to July)	2,328 (2.7)	797 (2.4)	346 (2.0)	619 (2.7)	566 (4.7)	4 (0.0)	1 (0.0)	0 (0.0)	3 (0.1)	0 (0.0)
Size of healthcare facilities, n (%)										
Less than 200 beds	5,072 (5.9)	1,700 (5.2)	1,165 (6.6)	1,420 (6.2)	787 (6.6)	541 (5.0)	66 (3.2)	54 (4.9)	152 (5.6)	269 (5.5)
200 to 499 beds	48,569 (56.8)	17,932 (54.5)	10,427 (59.2)	13,476 (58.5)	6,734 (56.2)	5,907 (54.9)	1,100 (53.3)	597 (54.3)	1,529 (56.0)	2,681 (55.0)
500 or more beds	31,909 (37.3)	13,277 (40.3)	6,026 (34.2)	8,150 (35.4)	4,456 (37.2)	4,316 (40.1)	898 (43.5)	449 (40.8)	1,047 (38.4)	1,922 (39.4)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 5. Distribution of infants <1 year of age who are diagnosed in the outpatient setting, who are hospitalized, who required oxygen use, or who required mechanical ventilation with RSV infection or influenza in Japan by month of age

Age (month)	0	1	2	3	4	5	6	7	8	9	10	11
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
RSV infection												
All children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	4,311 (3.9)	15,885 (14.5)	16,961 (15.5)	12,944 (11.8)	10,884 (10.0)	9,036 (8.3)	7,830 (7.2)	7,026 (6.4)	6,311 (5.8)	6,149 (5.6)	5,967 (5.5)	6,028 (5.5)
All children: Total number of hospitalized patients per age group, n (%)	1,271 (2.3)	8,223 (15.2)	9,500 (17.6)	6,901 (12.8)	5,230 (9.7)	4,148 (7.7)	3,546 (6.6)	3,362 (6.2)	2,999 (5.5)	3,023 (5.6)	2,940 (5.4)	2,957 (5.5)
All children: Total number of patient who required mechanical ventilation per age group, n (%)	71 (4.8)	454 (30.8)	326 (22.1)	131 (8.9)	94 (6.4)	79 (5.4)	55 (3.7)	60 (4.1)	52 (3.5)	54 (3.7)	50 (3.4)	46 (3.1)
Healthy children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)												
	1,379 (1.8%)	9,044 (11.5%)	11,192 (14.2%)	9,200 (11.7%)	7,849 (10%)	6,654 (8.5%)	5,999 (7.6%)	5,759 (7.3%)	5,389 (6.9%)	5,343 (6.8%)	5,339 (6.8%)	5,396 (6.9%)
Healthy children: Total number of hospitalized patients per age group, n (%)	1,134 (2.2%)	7,691 (15.2%)	8,894 (17.6%)	6,500 (12.9%)	4,849 (9.6%)	3,841 (7.6%)	3,269 (6.5%)	3,152 (6.2%)	2,801 (5.5%)	2,819 (5.6%)	2,801 (5.5%)	2,776 (5.5%)
Healthy children: Total number of patient who required mechanical ventilation per age group, n (%)	62 (4.8)	419 (32.2)	291 (22.4)	121 (9.3)	83 (6.4)	57 (4.4)	45 (3.5)	50 (3.8)	42 (3.2)	46 (3.5)	44 (3.4)	42 (3.2)
All Children: Overall hospitalizations after diagnosis (n, % of outpatient diagnoses)												
Admissions within 0-6 days	570 (13.2)	3,884 (24.5)	4,477 (26.4)	3,245 (25.1)	2,449 (22.5)	1,935 (21.4)	1,659 (21.2)	1,606 (22.9)	1,416 (22.4)	1,434 (23.3)	1,381 (23.1)	1,407 (23.3)
Admissions within 0-13 days	570	3,912	4,496	3,258	2,460	1,949	1,672	1,613	1,423	1,446	1,386	1,409

	(13.2)	(24.6)	(26.5)	(25.2)	(22.6)	(21.6)	(21.4)	(23.0)	(22.5)	(23.5)	(23.2)	(23.4)
Admissions within 0-29 days	576	3,952	4,561	3,306	2,495	1,979	1,694	1,641	1,448	1,465	1,410	1,432
	(13.4)	(24.9)	(26.9)	(25.5)	(22.9)	(21.9)	(21.6)	(23.4)	(22.9)	(23.8)	(23.6)	(23.8)
Healthy Children: Overall hospitalizations after diagnosis												
(n, % of outpatient diagnoses)												
Admissions within 0-6 days	541	3,699	4,267	3,100	2,297	1,813	1,562	1,541	1,338	1,346	1,323	1,333
	(39.2)	(40.9)	(38.1)	(33.7)	(29.3)	(27.2)	(26.0)	(26.8)	(24.8)	(25.2)	(24.8)	(24.7)
Admissions within 0-13 days	541	3,726	4,283	3,112	2,306	1,826	1,573	1,547	1,345	1,356	1,325	1,333
	(39.2)	(41.2)	(38.3)	(33.8)	(29.4)	(27.4)	(26.2)	(26.9)	(25.0)	(25.4)	(24.8)	(24.7)
Admissions within 0-29 days	545	3,754	4,331	3,156	2,336	1,848	1,593	1,573	1,368	1,374	1,348	1,354
	(39.5)	(41.5)	(38.7)	(34.3)	(29.8)	(27.8)	(26.6)	(27.3)	(25.4)	(25.7)	(25.2)	(25.1)
Influenza												
All children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	215 (0.9)	1,178 (4.7)	1,823 (7.3)	1,908 (7.6)	1,816 (7.3)	1,801 (7.2)	2,088 (8.3)	2,315 (9.2)	2,604 (10.4)	2,934 (11.7)	3,121 (12.5)	3,233 (12.9)
All children: Total number of hospitalized patients per age group, n (%)	53 (1.6)	405 (12.2)	655 (19.7)	519 (15.6)	327 (9.8)	182 (5.5)	193 (5.8)	168 (5.0)	184 (5.5)	206 (6.2)	222 (6.7)	215 (6.5)
All children: Total number of patient who required mechanical ventilation per age group, n (%)	0 (0.0)	1 (7.7)	4 (30.8)	0 (0.0)	2 (15.4)	1 (7.7)	0 (0.0)	2 (15.4)	0 (0.0)	1 (7.7)	1 (7.7)	1 (7.7)
Healthy children: Total number of patient who are diagnosed in the outpatient setting per age group, n (%)	192 (0.8%)	1,086 (4.6%)	1,723 (7.3%)	1,810 (7.7%)	1,708 (7.3%)	1,678 (7.1%)	1,949 (8.3%)	2,174 (9.3%)	2,443 (10.4%)	2,739 (11.7%)	2,944 (12.5%)	3,028 (12.9%)
Healthy children: Total number of hospitalized patients per age group, n (%)	51 (1.6%)	394 (12.5%)	637 (20.1%)	500 (15.8%)	315 (10%)	167 (5.3%)	183 (5.8%)	153 (4.8%)	174 (5.5%)	189 (6%)	202 (6.4%)	199 (6.3%)
Healthy children: Total number of patient who required mechanical ventilation per age group, n (%)	0 (0%)	1 (14.3%)	3 (42.9%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (14.3%)	0 (0%)	1 (14.3%)	1 (14.3%)	0 (0%)

All Children: Overall hospitalizations after diagnosis

(n, % of outpatient diagnoses)

Admissions within 0-6 days	17 (7.9)	128 (10.9)	216 (11.8)	174 (9.1)	124 (6.8)	77 (4.3)	66 (3.2)	56 (2.4)	65 (2.5)	82 (2.8)	90 (2.9)	82 (2.5)
Admissions within 0-13 days	17 (7.9)	129 (11.0)	217 (11.9)	174 (9.1)	125 (6.9)	77 (4.3)	66 (3.2)	56 (2.4)	65 (2.5)	82 (2.8)	90 (2.9)	85 (2.6)
Admissions within 0-29 days	17 (7.9)	129 (11.0)	217 (11.9)	174 (9.1)	126 (6.9)	77 (4.3)	67 (3.2)	56 (2.4)	65 (2.5)	82 (2.8)	92 (2.9)	86 (2.7)

Healthy Children: Overall hospitalizations after diagnosis

(n, % of outpatient diagnoses)

Admissions within 0-6 days	16 (8.3)	121 (11.1)	206 (12.0)	163 (9.0)	119 (7.0)	69 (4.1)	61 (3.1)	47 (2.2)	58 (2.4)	70 (2.6)	76 (2.6)	74 (2.4)
Admissions within 0-13 days	16 (8.3)	122 (11.2)	207 (12.0)	163 (9.0)	120 (7.0)	69 (4.1)	61 (3.1)	47 (2.2)	58 (2.4)	70 (2.6)	76 (2.6)	77 (2.5)
Admissions within 0-29 days	16 (8.3)	122 (11.2)	207 (12.0)	163 (9.0)	121 (7.1)	69 (4.1)	62 (3.2)	47 (2.2)	58 (2.4)	70 (2.6)	77 (2.6)	78 (2.6)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 6. Annual number of cases by month

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2011	4	56	0.1	36	0.3	114	0.1	954	0.6
	5	44	0.0	22	0.2	92	0.1	379	0.2
	6	60	0.1	6	0.1	103	0.1	184	0.1
	7	77	0.1	1	0.0	145	0.1	50	0.0
	8	127	0.1	0	0.0	231	0.1	17	0.0
	9	178	0.2	1	0.0	398	0.2	23	0.0
	10	219	0.2	0	0.0	466	0.3	54	0.0
	11	267	0.3	9	0.1	596	0.3	164	0.1
	12	451	0.5	19	0.2	845	0.5	578	0.4
	1	252	0.3	74	0.7	550	0.3	1,937	1.3
	2	124	0.1	111	1.0	276	0.2	2,752	1.8
	3	129	0.1	77	0.7	287	0.2	1,423	0.9
2012	4	72	0.1	40	0.4	202	0.1	747	0.5
	5	52	0.1	11	0.1	117	0.1	236	0.2
	6	80	0.1	6	0.1	164	0.1	99	0.1
	7	83	0.1	4	0.0	183	0.1	114	0.1
	8	206	0.2	6	0.1	273	0.2	91	0.1
	9	354	0.4	0	0.0	1,139	0.6	74	0.0
	10	596	0.7	1	0.0	1,430	0.8	66	0.0
	11	599	0.7	4	0.0	1,291	0.7	133	0.1
	12	699	0.8	22	0.2	1,430	0.8	499	0.3
	1	401	0.4	177	1.6	887	0.5	2,753	1.8
	2	188	0.2	154	1.4	488	0.3	2,524	1.6
	3	191	0.2	84	0.8	461	0.3	1,275	0.8
2013	4	160	0.2	48	0.4	376	0.2	755	0.5
	5	132	0.1	37	0.3	297	0.2	626	0.4
	6	116	0.1	7	0.1	248	0.1	139	0.1
	7	199	0.2	1	0.0	332	0.2	58	0.0
	8	372	0.4	0	0.0	660	0.4	22	0.0
	9	651	0.7	1	0.0	1,621	0.9	19	0.0
	10	743	0.8	1	0.0	1,603	0.9	62	0.0
	11	850	0.9	8	0.1	1,733	1.0	229	0.1
	12	894	1.0	36	0.3	1,663	0.9	652	0.4
	1	542	0.6	222	2.0	1,142	0.6	2,746	1.8
	2	285	0.3	284	2.5	679	0.4	3,870	2.5
	2014	3	232	0.3	212	1.9	607	0.3	2,806
4		243	0.3	124	1.1	700	0.4	2,203	1.4
5		204	0.2	43	0.4	540	0.3	846	0.6

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2015	6	176	0.2	9	0.1	422	0.2	240	0.2
	7	225	0.2	2	0.0	472	0.3	126	0.1
	8	379	0.4	4	0.0	689	0.4	50	0.0
	9	850	0.9	1	0.0	2,206	1.2	93	0.1
	10	937	1.0	3	0.0	1,933	1.1	140	0.1
	11	1,405	1.6	26	0.2	2,542	1.4	504	0.3
	12	1,781	2.0	210	1.9	3,307	1.9	3,406	2.2
	1	794	0.9	545	4.9	1,653	0.9	8,043	5.2
	2	467	0.5	162	1.4	1,025	0.6	2,653	1.7
	3	433	0.5	87	0.8	1,060	0.6	1,133	0.7
	4	406	0.4	50	0.4	1,060	0.6	850	0.6
	2016	5	218	0.2	17	0.2	593	0.3	421
6		240	0.3	7	0.1	523	0.3	178	0.1
7		336	0.4	4	0.0	530	0.3	120	0.1
8		555	0.6	2	0.0	913	0.5	82	0.1
9		905	1.0	6	0.1	2,333	1.3	116	0.1
10		1,322	1.5	10	0.1	2,658	1.5	257	0.2
11		1,922	2.1	22	0.2	3,442	1.9	462	0.3
12		2,070	2.3	43	0.4	3,611	2.0	868	0.6
1		874	1.0	222	2.0	1,676	0.9	3,103	2.0
2		401	0.4	689	6.2	943	0.5	7,554	4.9
3		338	0.4	395	3.5	852	0.5	4,625	3.0
2017		4	351	0.4	158	1.4	779	0.4	2,174
	5	287	0.3	34	0.3	671	0.4	610	0.4
	6	255	0.3	4	0.0	584	0.3	141	0.1
	7	475	0.5	7	0.1	838	0.5	90	0.1
	8	671	0.7	3	0.0	1,129	0.6	75	0.0
	9	1,400	1.5	4	0.0	3,197	1.8	119	0.1
	10	1,848	2.0	24	0.2	3,456	2.0	485	0.3
	11	1,311	1.5	45	0.4	2,376	1.3	859	0.6
	12	997	1.1	133	1.2	1,906	1.1	2,094	1.4
	1	518	0.6	408	3.6	1,187	0.7	4,963	3.2
	2	299	0.3	375	3.4	820	0.5	4,666	3.0
	3	381	0.4	205	1.8	951	0.5	2,478	1.6
4	484	0.5	136	1.2	1,127	0.6	1,980	1.3	
5	509	0.6	55	0.5	1,046	0.6	1,038	0.7	
6	557	0.6	16	0.1	1,004	0.6	351	0.2	
7	1,071	1.2	11	0.1	1,767	1.0	319	0.2	
8	2,434	2.7	20	0.2	4,025	2.3	356	0.2	

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2018	9	2,781	3.1	12	0.1	5,531	3.1	431	0.3
	10	1,692	1.9	27	0.2	3,154	1.8	491	0.3
	11	1,031	1.1	53	0.5	1,979	1.1	825	0.5
	12	976	1.1	247	2.2	1,818	1.0	3,546	2.3
	1	675	0.7	600	5.4	1,464	0.8	8,322	5.4
	2	490	0.5	404	3.6	1,118	0.6	5,553	3.6
	3	581	0.6	159	1.4	1,210	0.7	2,203	1.4
	4	637	0.7	73	0.7	1,288	0.7	1,109	0.7
	5	627	0.7	21	0.2	1,217	0.7	391	0.3
	6	657	0.7	14	0.1	1,239	0.7	227	0.1
	7	1,364	1.5	8	0.1	2,245	1.3	190	0.1
	8	2,031	2.2	8	0.1	3,787	2.1	161	0.1
2019	9	2,166	2.4	6	0.1	3,989	2.3	235	0.2
	10	1,352	1.5	14	0.1	2,546	1.4	358	0.2
	11	732	0.8	28	0.3	1,485	0.8	490	0.3
	12	819	0.9	215	1.9	1,526	0.9	2,432	1.6
	1	584	0.6	1,086	9.7	1,274	0.7	11,605	7.6
	2	530	0.6	353	3.2	1,036	0.6	3,923	2.6
	3	673	0.7	74	0.7	1,265	0.7	1,093	0.7
	4	821	0.9	68	0.6	1,534	0.9	1,024	0.7
	5	597	0.7	36	0.3	1,177	0.7	706	0.5
	6	528	0.6	13	0.1	975	0.6	295	0.2
	7	1,386	1.5	12	0.1	2,418	1.4	317	0.2
	8	2,328	2.6	13	0.1	3,826	2.2	348	0.2
2020	9	2,671	3.0	51	0.5	4,241	2.4	953	0.6
	10	1,492	1.7	48	0.4	2,493	1.4	707	0.5
	11	731	0.8	92	0.8	1,384	0.8	915	0.6
	12	662	0.7	547	4.9	1,322	0.7	4,537	3.0
	1	410	0.5	663	5.9	971	0.5	5,536	3.6
	2	355	0.4	153	1.4	799	0.5	1,452	0.9
	3	276	0.3	26	0.2	634	0.4	431	0.3
	4	140	0.2	6	0.1	361	0.2	136	0.1
	5	27	0.0	1	0.0	112	0.1	33	0.0
	6	29	0.0	0	0.0	231	0.1	33	0.0
	7	68	0.1	0	0.0	697	0.4	27	0.0
	8	59	0.1	0	0.0	649	0.4	22	0.0
9	106	0.1	1	0.0	592	0.3	29	0.0	
10	159	0.2	0	0.0	607	0.3	53	0.0	
11	172	0.2	0	0.0	521	0.3	91	0.1	

Year	Month	RSV - Inpatients		Influenza - Inpatients		RSV - Outpatients		Influenza - Outpatients	
		n	%	n	%	n	%	n	%
2021	12	182	0.2	1	0.0	487	0.3	123	0.1
	1	163	0.2	1	0.0	434	0.2	104	0.1
	2	228	0.3	1	0.0	417	0.2	88	0.1
	3	465	0.5	1	0.0	621	0.4	106	0.1
	4	933	1.0	1	0.0	1,265	0.7	137	0.1
	5	1,537	1.7	0	0.0	2,163	1.2	141	0.1
	6	2,348	2.6	0	0.0	3,881	2.2	144	0.1
	7	3,135	3.5	0	0.0	5,560	3.1	108	0.1
	8	1,884	2.1	0	0.0	3,451	2.0	65	0.0
	9	772	0.9	0	0.0	1,369	0.8	37	0.0
	10	326	0.4	0	0.0	726	0.4	29	0.0
	11	228	0.3	1	0.0	563	0.3	47	0.0
2022	12	377	0.4	1	0.0	671	0.4	95	0.1
	1	330	0.4	2	0.0	588	0.3	184	0.1
	2	160	0.2	0	0.0	373	0.2	149	0.1
	3	145	0.2	0	0.0	280	0.2	132	0.1
	4	81	0.1	0	0.0	213	0.1	108	0.1
	5	155	0.2	0	0.0	437	0.2	82	0.1
	6	404	0.4	0	0.0	745	0.4	60	0.0
7	1,135	1.3	2	0.0	2,277	1.3	233	0.2	

Supplementary Table 7. Baseline characteristics of children <5 years of age who are hospitalized with RSV infection by age group and COVID-19 era

	Age <6 months			Age 6-11 months			Age 1-<2- years			Age 2-<5 years		
	Pre- COVID- 19	During COVID- 19	2021 season	Pre- COVID- 19	During COVID- 19	2021 season	Pre- COVID- 19	During COVID- 19	2021 season	Pre- COVID- 19	During COVID- 19	2021 season
	Total number of patients per age group per time period, n (relative % by age group)	14,877 (39.3)	6,106 (36.4)	4,456 (35.9)	8,311 (21.9)	2,536 (15.1)	1,771 (14.3)	10,142 (26.8)	4,574 (27.2)	3,438 (27.7)	4,537 (12.0)	3,573 (21.3)
Sex, n (%)												
Female	6,501 (43.7)	2,760 (45.2)	2,023 (45.4)	3,518 (42.3)	1,067 (42.1)	732 (41.3)	4,775 (47.1)	2,074 (45.3)	1,582 (46.0)	2,228 (49.1)	1,813 (50.7)	1,396 (51.1)
Male	8,376 (56.3)	3,346 (54.8)	2,433 (54.6)	4,793 (57.7)	1,469 (57.9)	1,039 (58.7)	5,367 (52.9)	2,500 (54.7)	1,856 (54.0)	2,309 (50.9)	1,760 (49.3)	1,335 (48.9)
Age, months												
Mean (SD)	2.6 (1.4)	2.4 (1.4)	2.3 (1.4)	8.4 (1.7)	8.5 (1.7)	8.4 (1.7)	16.5 (3.3)	17.3 (3.4)	17.4 (3.4)	33.7 (8.5)	34.0 (8.8)	33.8 (8.7)
Median (IQR)	2.0 (1.0-4.0)	2.0 (1.0-3.0)	2.0 (1.0-3.0)	8.0 (7.0-10.0)	8.0 (7.0-10.0)	8.0 (7.0-10.0)	16.0 (14.0-19.0)	17.0 (14.0-20.0)	17.0 (15.0-20.0)	31.0 (27.0-39.0)	31.0 (27.0-39.0)	31.0 (27.0-39.0)
Season by year, n (%)												
2016 (May 2016 to April 2017)	758 (5.1)	0 (0.0)	0 (0.0)	425 (5.1)	0 (0.0)	0 (0.0)	353 (3.5)	0 (0.0)	0 (0.0)	146 (3.2)	0 (0.0)	0 (0.0)
2017 (May 2017 to April 2018)	5,148 (34.6)	0 (0.0)	0 (0.0)	2,987 (35.9)	0 (0.0)	0 (0.0)	3,588 (35.4)	0 (0.0)	0 (0.0)	1,711 (37.7)	0 (0.0)	0 (0.0)
2018 (May 2018 to April 2019)	5,105 (34.3)	0 (0.0)	0 (0.0)	2,754 (33.1)	0 (0.0)	0 (0.0)	3,148 (31.0)	0 (0.0)	0 (0.0)	1,349 (29.7)	0 (0.0)	0 (0.0)
2019 (May 2019 to April 2020)	3,866 (26.0)	514 (8.4)	0 (0.0)	2,145 (25.8)	237 (9.3)	0 (0.0)	3,053 (30.1)	260 (5.7)	0 (0.0)	1,331 (29.3)	170 (4.8)	0 (0.0)
2020 (May to December)	0	304	0	0	166	0	0	238	0	0	94	0

	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
No record of these comorbidities	5,782	4,263	7,815	2,391	1,675	9,869	4,475	3,361	4,389	3,479	2,655	5,782
	(94.7)	(95.7)	(94.0)	(94.3)	(94.6)	(97.3)	(97.8)	(97.8)	(96.7)	(97.4)	(97.2)	(94.7)
Palivizumab use, n (%)												
Yes	343	95	47	211	59	38	174	52	37	15	13	9
	(2.3)	(1.6)	(1.1)	(2.5)	(2.3)	(2.1)	(1.7)	(1.1)	(1.1)	(0.3)	(0.4)	(0.3)
No record of use	14,534	6,011	4,409	8,100	2,477	1,733	9,968	4,522	3,401	4,522	3,560	2,722
	(97.7)	(98.4)	(98.9)	(97.5)	(97.7)	(97.9)	(98.3)	(98.9)	(98.9)	(99.7)	(99.6)	(99.7)
Size of healthcare facilities, n (%)												
Less than 200 beds	679	358	255	489	196	132	524	350	254	240	302	242
	(4.6)	(5.9)	(5.7)	(5.9)	(7.7)	(7.5)	(5.2)	(7.7)	(7.4)	(5.3)	(8.5)	(8.9)
200 to 499 beds	8,137	3,296	2,395	4,930	1,501	1,028	5,994	2,599	1,962	2,595	1,982	1,520
	(54.7)	(54.0)	(53.7)	(59.3)	(59.2)	(58.0)	(59.1)	(56.8)	(57.1)	(57.2)	(55.5)	(55.7)
500 or more beds	6,061	2,452	1,806	2,892	839	611	3,624	1,625	1,222	1,702	1,289	969
	(40.7)	(40.2)	(40.5)	(34.8)	(33.1)	(34.5)	(35.7)	(35.5)	(35.5)	(37.5)	(36.1)	(35.5)

Rounding may create totals slightly over or below 100% in some cases.

Supplementary Table 8. Baseline characteristics of children <5 years of age who are hospitalized with influenza in Japan by age group and COVID-19 era

	Age <6 months			Age 6-11 months			Age 1-<2- years			Age 2-<5 years		
	Pre- COVID- 19	During COVID- 19	2021 season	Pre- COVID- 19	During COVID- 19	2021 season	Pre- COVID- 19	During COVID- 19	2021 season	Pre- COVID- 19	During COVID- 19	2021 season
Total number of patients per age group per time period, n (relative % by age group)	1,125 (20.4)	155 (18.0)	1 (16.7)	568 (10.3)	97 (11.3)	1 (16.7)	1,384 (25.1)	275 (31.9)	3 (50.0)	2,431 (44.1)	334 (38.8)	1 (16.7)
Sex, n (%)												
Female	528 (46.9)	63 (40.6)	1 (100)	260 (45.8)	38 (39.2)	1 (100)	620 (44.8)	118 (42.9)	0 (0.0)	1,035 (42.6)	126 (37.7)	0 (0.0)
Male	597 (53.1)	92 (59.4)	0 (0.0)	308 (54.2)	59 (60.8)	0 (0.0)	764 (55.2)	157 (57.1)	3 (100)	1,396 (57.4)	208 (62.3)	1 (100)
Age, months												
Mean (SD)	2.6 (1.2)	2.6 (1.3)	0.0 (.)	8.6 (1.7)	8.5 (1.7)	10.0 (.)	17.3 (3.4)	17.3 (3.3)	19.0 (1.7)	40.2 (10.6)	40.3 (10.6)	27.0 (.)
Median (IQR)	2.0 (2.0-3.0)	3.0 (2.0-4.0)	0.0 (0.0-0.0)	9.0 (7.0-10.0)	9.0 (7.0-10.0)	10.0 (10.0-10.0)	17.0 (14.0-20.0)	17.0 (14.0-20.0)	20.0 (17.0-20.0)	40.0 (31.0-49.0)	40.0 (31.0-49.0)	27.0 (27.0-27.0)
Season by year, n (%)												
2016 (May 2016 to April 2017)	255 (22.7)	0 (0.0)	0 (0.0)	108 (19.0)	0 (0.0)	0 (0.0)	276 (19.9)	0 (0.0)	0 (0.0)	485 (20.0)	0 (0.0)	0 (0.0)
2017 (May 2017 to April 2018)	303 (26.9)	0 (0.0)	0 (0.0)	174 (30.6)	0 (0.0)	0 (0.0)	396 (28.6)	0 (0.0)	0 (0.0)	804 (33.1)	0 (0.0)	0 (0.0)
2018 (May 2018 to April 2019)	423 (37.6)	0 (0.0)	0 (0.0)	186 (32.7)	0 (0.0)	0 (0.0)	490 (35.4)	0 (0.0)	0 (0.0)	796 (32.7)	0 (0.0)	0 (0.0)
2019 (May 2019 to April 2020)	144 (12.8)	152 (98.1)	0 (0.0)	100 (17.6)	94 (96.9)	0 (0.0)	222 (16.0)	269 (97.8)	0 (0.0)	346 (14.2)	333 (99.7)	0 (0.0)

2020 (May to December)	0	1	0	0	2	0	0	0	0	0	0	0
	(0.0)	(0.6)	(0.0)	(0.0)	(2.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
2021 (January to December)	0	1	1	0	1	1	0	3	3	0	1	1
	(0.0)	(0.6)	(100)	(0.0)	(1.0)	(100)	(0.0)	(1.1)	(100)	(0.0)	(0.3)	(100)
2022 (January to July)	0	1	0	0	0	0	0	3	0	0	0	0
	(0.0)	(0.6)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(1.1)	(0.0)	(0.0)	(0.0)	(0.0)
Comorbidity during baseline period, n (%)												
Down syndrome	1	1	0	1	1	0	0	0	0	4	0	0
	(0.1)	(0.6)	(0.0)	(0.2)	(1.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.2)	(0.0)	(0.0)
Congenital heart disease	23	1	0	16	4	0	13	2	0	8	1	0
	(2.0)	(0.6)	(0.0)	(2.8)	(4.1)	(0.0)	(0.9)	(0.7)	(0.0)	(0.3)	(0.3)	(0.0)
Bronchopulmonary dysplasia	1	0	0	1	0	0	1	0	0	0	0	0
	(0.1)	(0.0)	(0.0)	(0.2)	(0.0)	(0.0)	(0.1)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Prematurity	19	3	0	16	6	0	1	1	0	1	0	0
	(1.7)	(1.9)	(0.0)	(2.8)	(6.2)	(0.0)	(0.1)	(0.4)	(0.0)	(0.0)	(0.0)	(0.0)
Immunodeficiency	1	0	0	4	1	0	3	1	0	8	0	0
	(0.1)	(0.0)	(0.0)	(0.7)	(1.0)	(0.0)	(0.2)	(0.4)	(0.0)	(0.3)	(0.0)	(0.0)
Pulmonary hypoplasia	0	1	0	0	0	0	0	0	0	0	0	0
	(0.0)	(0.6)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Airway stenosis	0	0	0	0	0	0	1	1	0	0	0	0
	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(0.4)	(0.0)	(0.0)	(0.0)	(0.0)
Esophageal atresia	0	0	0	0	0	0	0	0	0	0	0	0
	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
Congenital metabolic disorder	1	0	0	4	0	0	11	2	0	25	0	0
	(0.1)	(0.0)	(0.0)	(0.7)	(0.0)	(0.0)	(0.8)	(0.7)	(0.0)	(1.0)	(0.0)	(0.0)
Neuromuscular disorder	0	0	0	5	3	0	17	2	0	28	1	0
	(0.0)	(0.0)	(0.0)	(0.9)	(3.1)	(0.0)	(1.2)	(0.7)	(0.0)	(1.2)	(0.3)	(0.0)

Cystic fibrosis	0	0	0	0	0	0	0	0	0	0	0	0
	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
No record of these comorbidities	1,082	150	1	529	85	1	1,339	269	3	2,367	332	1
	(96.2)	(96.8)	(100.0)	(93.1)	(87.6)	(100.0)	(96.7)	(97.8)	(100.0)	(97.4)	(99.4)	(100.0)
Palivizumab use, n (%)												
Yes	11	2	0	15	5	0	17	1	0	2	1	0
	(1.0)	(1.3)	(0.0)	(2.6)	(5.2)	(0.0)	(1.2)	(0.4)	(0.0)	(0.1)	(0.3)	(0.0)
No record of use	1,114	153	1	553	92	1	1,367	274	3	2,429	333	1
	(99.0)	(98.7)	(100)	(97.4)	(94.8)	(100)	(98.8)	(99.6)	(100)	(99.9)	(99.7)	(100)
Size of healthcare institution, n (%)												
Less than 200 beds	35	2	0	19	1	0	71	14	0	93	13	0
	(3.1)	(1.3)	(0.0)	(3.3)	(1.0)	(0.0)	(5.1)	(5.1)	(0.0)	(3.8)	(3.9)	(0.0)
200 to 499 beds	595	76	1	299	52	1	776	143	2	1,330	175	1
	(52.9)	(49.0)	(100)	(52.6)	(53.6)	(100)	(56.1)	(52.0)	(66.7)	(54.7)	(52.4)	(100)
500 or more beds	495	77	0	250	44	0	537	118	1	1,008	146	0
	(44.0)	(49.7)	(0.0)	(44.0.)	(45.4)	(0.0)	(38.8)	(42.9)	(33.3)	(41.5)	(43.7)	(0.0)

Rounding may create totals slightly over or below 100% in some cases.